New facility to support advancements in molecular diagnostics, rare disease research, and industrial microbiology ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...

In a world grappling with an ever-evolving geopolitical crisis, fostering cross-pollination of ideas, research, and policies ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Colossal, a leading biosciences company working to combat environmental dangers and revive extinct species, has reached a new ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...